Abstract
A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan. The new drug had been added to the long-standing treatment with risperidone. Diagnosed with diabetic ketoacidosis, he was given insulin and saline with discontinuation of all antipsychotics. Ultimately, diabetes was controlled by dietary therapy alone despite reintroduction of risperidone. The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.
